Skip to content
Bored Studies
RecruitingAccepts healthy volunteers

Interrogation of Exosome-mediated Intercellular Signaling in Patients With Pancreatic Cancer

Memorial Sloan Kettering Cancer Center · with Weill Medical College of Cornell University, National Institutes of Health (NIH) · NCT02393703

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Accepted
Study type
Observational
Target enrollment
181
US sites recruiting
1
Study start
March 2015
Record last updated
February 9, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The purpose of this study is to isolate and analyze exosomes, which are tiny carriers of important proteins and nucleic acids that serve as messenger systems in the blood and tissue. Blood and tissue from patients with pancreatic cancer will be compared with blood and tissue from patients with noncancerous pancreatic disease. Including patients without cancer will allow the investigators to establish "normal" values, which currently do not exist. The investigators will then look to see whether exosome activity has a connection to disease recurrence and outcomes in patients. The results of this study will be the basis for future studies exploring this area.

Conditions: Pancreatic Cancer; Benign Pancreatic Disease

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • All patients ≥ 18 years of age undergoing pancreaticoduodenectomy, partial or complete pancreatectomy, and duodenal ampullectomy for presumed ductal adenocarcinoma, intraductal papillary mucinous neoplasm (IPMN) or pancreatic neuroendocrine tumors, without an invasive component; or other benign pancreatic disease will be eligible.
  • For third part of the study, recipient of neoadjuvant chemotherapy will be accrued to the neoadjuvant group (25 patients). Patients without neoadjuvant chemotherapy will be accrued to the non-neoadjuvant group (25 patients).

Exclusion Criteria

  • The presence of metastatic disease or disease that precludes resection
  • For first and second part of the study, receipt of neoadjuvant chemotherapy or radiation for the index cancer within 6 months of being enrolled in the study
  • For third part of the study, receipt of neoadjuvant radiation for the index cancer within 6 months of being enrolled in the study
  • INR >2
  • Known clotting factor deficiency or hypercoagulable state
  • Any patient with the need or anticipated need for full anti-coagulation during hospitalization for the resection.
  • Receipt of antiplatelet agents (other than aspirin) in the preceding week prior to resection.
  • IPMN or pancreatic neuroendocrine tumors by radiographic imaging with high suspicion for invasive component Additionally, if at the discretion of the operating surgeon, blood collection would lead to undue morbidity, the patient will be excluded and replaced

Recruiting US locations

  • Memorial Sloan Kettering Cancer Center

    New York, NY 10065

    Site contact: William R Jarnagin, MD · 212-639-7601

Study contacts (from the official record)

  • William Jarnagin, MD · 212-639-7601
  • Peter Kingham, MD · 212-639-5260
All healthy volunteers studies in New York →
Interrogation of Exosome-mediated Intercellular Signaling in… (NCT02393703) | Bored Studies